Skip to content
2000
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Montelukast, a leukotriene receptor antagonist, is frequently used to treat asthma and allergic rhinitis. Despite its effectiveness, there are rising concerns about potential neuropsychiatric side effects, such as agitation, anxiety, depression, hallucinations, sleep disturbances, and suicidal ideation. It is crucial to examine clinical evidence to better understand these adverse reactions and ensure patient safety.

This review aims to assess the clinical evidence regarding neuropsychiatric side effects associated with montelukast use. By analyzing studies from various databases, the goal is to equip healthcare professionals with a thorough understanding of these side effects, encouraging cautious use of montelukast in clinical settings.

The literature was searched in databases, such as Medline/Pubmed/PMC, Scopus, Web of Science, Google Scholar, ScienceDirect, Ebsco, Embase, and reference lists, to identify publications relevant to neuropsychiatric side effects associated with the use of montelukast.

Various studies consistently reported a range of neuropsychiatric adverse reactions, including agitation, anxiety, depression, hallucinations, sleep disturbances, and suicidal ideation. The findings indicated a notable association between montelukast and these neuropsychiatric symptoms across various patient populations and age groups.

Clinicians should be aware of the serious mental health side effects of montelukast.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882340597241218062725
2024-01-01
2025-09-29

  • From This Site

    /content/journals/nemj/10.2174/0102506882340597241218062725
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/nemj/5/1/NEMJ-5-E02506882340597.html?itemId=/content/journals/nemj/10.2174/0102506882340597241218062725&mimeType=html&fmt=ahah

References

  1. MatsuseH. KohnoS. Leukotriene receptor antagonists pranlukast and montelukast for treating asthma.Expert Opin. Pharmacother.201415335336310.1517/14656566.2014.87224124350802
     [Google Scholar]
  2. Dal NegroD.R. PiskorzP. VivesR. GuileraM. Sazonov KocevarV. BadiaX. Healthcare utilisation and costs associated with adding montelukast to current therapy in patients with mild to moderate asthma and co-morbid allergic rhinitis: Practical study.PharmacoEconomics200725866567610.2165/00019053‑200725080‑0000417640108
     [Google Scholar]
  3. StormsW. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction.Expert Opin. Pharmacother.20078132173218710.1517/14656566.8.13.217317714069
     [Google Scholar]
  4. DuongM. AminR. BaatjesA.J. KritzingerF. QiY. MeghjiZ. LouW. GrasemannH. O’ByrneP.M. SubbaraoP. The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction.J. Allergy Clin. Immunol.20121302535539.e310.1016/j.jaci.2012.02.05122534533
     [Google Scholar]
  5. NayakA. LangdonR.B. Montelukast in the treatment of allergic rhinitis: An evidence-based review.Drugs200767688790110.2165/00003495‑200767060‑0000517428106
     [Google Scholar]
  6. BenningerMS WatersH Montelukast: Pharmacology, safety, tolerability and efficacy.Clinical Medicine. Therapeutics.2009CMT-S114710.4137/CMT.S1147
     [Google Scholar]
  7. KittanaN. HattabS. Ziyadeh-IsleemA. JaradatN. ZaidA.N. Montelukast, current indications and prospective future applications.Expert Rev. Respir. Med.201610994395610.1080/17476348.2016.120753327485393
     [Google Scholar]
  8. RamakrishnanR. MigoyaE. KnorrB. A population pharmacokinetic model for montelukast disposition in adults and children.Pharm. Res.200522453254010.1007/s11095‑005‑2493‑y15846460
     [Google Scholar]
  9. FilppulaA.M. LaitilaJ. NeuvonenP.J. BackmanJ.T. Reevaluation of the microsomal metabolism of montelukast: Major contribution by CYP2C8 at clinically relevant concentrations.Drug Metab. Dispos.201139590491110.1124/dmd.110.03768921289076
     [Google Scholar]
  10. KaronenT. NeuvonenP.J. BackmanJ.T. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.Br. J. Clin. Pharmacol.201273225726710.1111/j.1365‑2125.2011.04086.x21838784
     [Google Scholar]
  11. WalskyR.L. ObachR.S. GamanE.A. GleesonJ.P.R. ProctorW.R. Selective inhibition of human cytochrome P4502C8 by montelukast.Drug Metab. Dispos.200533341341810.1124/dmd.104.00276615608135
     [Google Scholar]
  12. WalskyR.L. GamanE.A. ObachR.S. Examination of 209 drugs for inhibition of cytochrome P450 2C8.J. Clin. Pharmacol.2005451687810.1177/009127000427064215601807
     [Google Scholar]
  13. HaarmanM.G. van HunselF. de VriesT.W. Adverse drug reactions of montelukast in children and adults.Pharmacol. Res. Perspect.201755e0034110.1002/prp2.34128971612
     [Google Scholar]
  14. GarafoniF. TelecheaH. GiachettoG. Neuropsychiatric adverse effects of montelukast.Arch. Pediatr. Urug.20199029094
     [Google Scholar]
  15. Sansing-FosterV. HaugN. MosholderA. CocorosN.M. BradleyM. MaY. PennapD. DeeE.C. TohS. PestineE. PetroneA.B. KimI. LyonsJ.G. EworukeE. Risk of psychiatric adverse events among montelukast users.J. Allergy Clin. Immunol. Pract.202191385393.e1210.1016/j.jaip.2020.07.05232795564
     [Google Scholar]
  16. FoxC.W. KhawC.L. GerkeA.K. LundB.C. Montelukast and neuropsychiatric events: A sequence symmetry analysis.J. Asthma202259122360236610.1080/02770903.2021.201870534979844
     [Google Scholar]
  17. CalapaiG. CasciaroM. MiroddiM. CalapaiF. NavarraM. GangemiS. Montelukast-induced adverse drug reactions: A review of case reports in the literature.Pharmacology2014941-2607010.1159/00036616425196099
     [Google Scholar]
  18. LeeY.J. KimC.K. Montelukast use over the past 20 years: Monitoring of its effects and safety issues.Clin. Experi. Pedia.2020631037638110.3345/cep.2019.0032532023405
     [Google Scholar]
  19. AschenbrennerD.S. New boxed warning for singulair.Am. J. Nur.202012072732590592
     [Google Scholar]
  20. ClarridgeK. ChinS. EworukeE. SeymourS. A boxed warning for montelukast: The FDA perspective.J. Alle. Clin. Immunol. Pract.2021972638264110.1016/j.jaip.2021.02.05733744471
     [Google Scholar]
  21. United Kingdom Medicines and Healthcare products Regulatory Agency. Drug Safety Update. Montelukast: Reminder of the risk of neuropsychiatric reactions.2024Available from: https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions
  22. US Food and Drug Administration. Drug Safety and Availability. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis.2020Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug (Accessed on: Jan 19, 2024).
  23. Health Canada. Health Product InfoWatch. Singulair (montelukast)2020Available online: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/health-product-infowatch/august-2020.html#a5.1 (Accessed on: May 12, 2024).
  24. Therapeutic Goods Administration. Department of Health and Aged Care Australia. Safety Alerts. Safety Alerts. Montelukast: Safety Review.2018Available from: https://www.tga.gov.au/news/safety-alerts/montelukast (Accessed on: May 12, 2024).
  25. Saudi Food and Drug Authority. Safety communication. Montelukast: reminder of the risk of neuropsychiatric reactions.2019Available from: https://www.sfda.gov.sa/ar/drug/about/sector_departments/national_pharmacovigilance_center/Documents/MontelukastSafetyCommunication.pdf (Accessed on: May 12, 2024).
  26. National Pharmaceutical Regulatory Agency. Montelukast sodium: Update on neuropsychiatric adverse reactions – obsessive-compulsive symptoms.2018 https://www.npra.gov.my/index.php/en/component/content/article/79-english/safety-alerts-main/safety-alert-2018/1761-montelukast-sodium-update-on-neuropsychiatric-adverse-reactions-obsessive-compulsive-symptoms.html?Itemid=1391 (Accessed on: May 11, 2024).
  27. Health Services Authority. Singapore. Drug Safety Update. Advisory on restriction on the use of montelukast and neuropsychiatric effects.2020 https://www.hsa.gov.sg/announcements/safety-alert/advisory-on-restriction-on-the-use-of-montelukast-and-neuropsychiatric-effects (Accessed on: May 11, 2024).
  28. United Kingdom Medicines and Healthcare products Regulatory Agency. Drug Safety Update. Montelukast (Singulair): Reminder of the risk of neuropsychiatric reactions.2019 https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions (Accessed on: Apr 30, 2024).
  29. MarchandMS Jonville-BeraAP Autret-LecaE Psychiatric disorders associated with montelukast: Data from the National Pharmacovigilance Database.Archives de pediatrie: organe officiel de la Societe francaise de pediatrie.201320326973
     [Google Scholar]
  30. Aldea PeronaA. García-SáizM. Sanz ÁlvarezE. Psychiatric disorders and montelukast in children: A disproportionality analysis of the VigiBase®.Drug Saf.2016391697810.1007/s40264‑015‑0360‑226620206
     [Google Scholar]
  31. WatsonS. KaminskyE. TaavolaH. AttallaM. YueQ.Y. Montelukast and nightmares: Further characterisation using data from VigiBase.Drug Saf.202245667568410.1007/s40264‑022‑01183‑235650509
     [Google Scholar]
  32. AliMM O'BrienCE ClevesMA MartinBC Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case‐control study.Pharmacoepidem. Drug Safe.201524443545
     [Google Scholar]
  33. Glockler-LaufS.D. FinkelsteinY. ZhuJ. FeldmanL.Y. ToT. Montelukast and neuropsychiatric events in children with asthma: A nested case–control study.J. Pediatr.2019209176182.e410.1016/j.jpeds.2019.02.00930905424
     [Google Scholar]
  34. Yilmaz BayerO. TurktasI. Ertoy KaragolH.I. SoysalS. YaparD. Neuropsychiatric adverse drug reactions induced by montelukast impair the quality of life in children with asthma.J. Asthma202259358058910.1080/02770903.2020.186162633287615
     [Google Scholar]
  35. JordanA. ToennesenL.L. EklöfJ. SivapalanP. MeteranH. BønnelykkeK. UlrikC.S. Stæhr JensenJ.U. Psychiatric adverse effects of montelukast: A nationwide cohort study.J. Allergy Clin. Immunol. Pract.202311720962103.e110.1016/j.jaip.2023.03.01036948487
     [Google Scholar]
  36. WallerstedtS.M. BrunlöfG. SundströmA. ErikssonA.L. Montelukast and psychiatric disorders in children.Pharmacoepidemiol. Drug Saf.200918985886410.1002/pds.179419551697
     [Google Scholar]
  37. PaljarviT. FortonJ. LucianoS. HerttuaK. FazelS. Analysis of neuropsychiatric diagnoses after montelukast initiation.JAMA Netw. Open202255e221364310.1001/jamanetworkopen.2022.1364335608857
     [Google Scholar]
  38. Al-ShamraniA. AlharbiS. KobeisyS. AlKhaterS.A. AlalkamiH. AlahmadiT. AlmutairiA. AlharbiA.S. YousefA.A. Adverse drug reactions (ADRs) of montelukast in children.Children2022911178310.3390/children911178336421233
     [Google Scholar]
  39. KimJ.H. LeeH. JeongD. LeeJ.H. KwonH.S. SongW.J. ChoY.S. KimY.J. ShinY.W. KimT.B. The risk of neuropsychiatric adverse events with use of leukotriene receptor antagonists in patients with asthma: Analysis of korea’s national health insurance sharing service database.J. Allergy Clin. Immunol. Pract.2023111236903699.e710.1016/j.jaip.2023.08.03737660732
     [Google Scholar]
  40. ShinE.Y. JinJ.H. KangM.K. YooY.S. LeeJ.H. SongW.J. KwonH.S. ChoY.S. MoonH.B. KimT.B. Adverse drug reactions of montelukast and pranlukast: Analysis of the Korea database.Asian Pac. J. Allergy Immunol.20221610.12932/AP‑030821‑120235278057
     [Google Scholar]
  41. ShimJ.S. KimM.H. KimM.H. ChoY.J. ChunE.M. Risk of neuropsychiatric diseases according to the use of a leukotriene receptor antagonist in middle-aged and older adults with asthma: A nationwide population-based study using health claims data in Korea.J. Allergy Clin. Immunol. Pract.20219124290429710.1016/j.jaip.2021.06.00734166842
     [Google Scholar]
  42. KangS.O. MinK.H. KimH.J. KimT.H. KimW. LeeK.E. The role of leukotriene modifying agent treatment in neuropsychiatric events of elderly asthma patients: A nested case control study.Asthma Res. Pract.202171410.1186/s40733‑021‑00070‑433731203
     [Google Scholar]
  43. ParkJ.S. ChoY.J. YunJ.Y. LeeH.J. YuJ. YangH.J. SuhD.I. Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: A self-controlled case series.Eur. Respir. J.2022605210246710.1183/13993003.02467‑202135595323
     [Google Scholar]
  44. BianS. LiL. WangZ. CuiL. XuY. GuanK. ZhaoB. WangL. YinJ. Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the food and drug administration (FDA) adverse event reporting system (FAERS).World Allergy Organ. J.2021141010059410.1016/j.waojou.2021.10059434659626
     [Google Scholar]
  45. AltaşU. AltaşZ.M. ÖzF. ÖzkarsM.Y. Evaluation of neuropsychiatric effects of montelukast–levocetirizine combination therapy in children with asthma and allergic rhinitis.Children2023108130110.3390/children1008130137628300
     [Google Scholar]
  46. PatilT. RaguindinJ.J. RadtkeM. SmigielJ. SavonaN. KavuruB. SekhriA. Evaluating the association of montelukast use on neuropsychiatry-related healthcare utilization and depression in COVID-19-hospitalized veterans: A nationwide VA observational cohort study.Clin. Drug Investig.202343860561910.1007/s40261‑023‑01292‑537498493
     [Google Scholar]
  47. ApataJ. LyonsJ.G. BradleyM.C. MaY. KempnerM.E. KimI. EworukeE. PennapD. MosholderA. Assessing the risk of intentional self-harm in montelukast users: An updated sentinel system analysis using ICD-10 coding.J. Asthma202361765366210.1080/02770903.2023.229306438064517
     [Google Scholar]
  48. SchumockG.T. LeeT.A. JooM.J. ValuckR.J. StaynerL.T. GibbonsR.D. Association between leukotriene-modifying agents and suicide: What is the evidence?Drug Saf.201134753354410.2165/11587260‑000000000‑0000021663330
     [Google Scholar]
  49. ByrneF. OluwoleB. WhyteV. FahyS. McGuinnessD. Delayed onset of neuropsychiatric effects associated with montelukast.Ir. J. Psychol. Med.201229212512710.1017/S079096670001743230199961
     [Google Scholar]
  50. UmetsuR. TanakaM. NakayamaY. KatoY. UedaN. NishibataY. HasegawaS. MatsumotoK. TakeyamaN. IguchiK. TanakaH. HinoiE. InagakiN. IndenM. MutoY. NakamuraM. Neuropsychiatric adverse events of montelukast: An analysis of real-world datasets and drug−gene interaction network.Front. Pharmacol.20211276427910.3389/fphar.2021.76427934987393
     [Google Scholar]
  51. MouY. SongQ. ZhaoC. FangH. RenC. SongX. Meta-analysis of the relationship between montelukast use and neuropsychiatric events in patients with allergic airway disease.Heliyon2023911e2184210.1016/j.heliyon.2023.e2184238034763
     [Google Scholar]
  52. BaiL. XuY. PanT. ZhangY. ZhouX. XuJ. Leukotriene receptor antagonists and risk of neuropsychiatric entities: A meta-analysis of observational studies.J. Allergy Clin. Immunol. Pract.2023113844854.e910.1016/j.jaip.2022.11.02136473625
     [Google Scholar]
  53. LoC.W.H. PathadkaS. QinS.X. FungL.W.Y. YanV.K.C. YiuH.H.E. BloomC.I. WongI.C.K. ChanE.W.Y. Neuropsychiatric events associated with montelukast in patients with asthma: A systematic review.Eur. Respir. Rev.20233216923007910.1183/16000617.0079‑202337758273
     [Google Scholar]
  54. LawS.W.Y. WongA.Y.S. AnandS. WongI.C.K. ChanE.W. Neuropsychiatric events associated with leukotriene-modifying agents: A systematic review.Drug Saf.201841325326510.1007/s40264‑017‑0607‑129076063
     [Google Scholar]
  55. YaoT.C. HuangJ.L. WuC.S. LuH.H. ChangY.C. ChenW.Y. KaoH.F. WuA.C. TsaiH.J. Comparative risk of neuropsychiatric adverse events associated with leukotriene-receptor antagonists versus inhaled corticosteroids.J. All. Clin. Immunol. Pract.2024S2213-219824009550096310.1016/j.jaip.2024.09.02839369853
     [Google Scholar]
  56. MarquesC.F. MarquesM.M. JustinoG.C. The mechanisms underlying montelukast’s neuropsychiatric effects new insights from a combined metabolic and multiomics approach.Life Sci.202231012105610.1016/j.lfs.2022.12105636228771
     [Google Scholar]
/content/journals/nemj/10.2174/0102506882340597241218062725
Loading
Montelukast-associated Serious Mental Health Adverse Effects: An Overview
NEW Emirates Medical J 5, e02506882340597 (2024); https://doi.org/10.2174/0102506882340597241218062725
/content/journals/nemj/10.2174/0102506882340597241218062725
/content/journals/nemj/10.2174/0102506882340597241218062725
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Agitation; Anxiety; Depression; Hallucinations; Mental health side effects; Montelukast; Neuropsychiatric events; Sleep disturbance; Suicidal ideation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test